文献

J-GLOBAL ID：202202270105840595   整理番号：22A0800260

統合失調症および大うつ病性障害の治療のための退院時の向精神薬投与患者の特性:EGUIDEプロジェクトからの全国調査【JST・京大機械翻訳】

The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder: A nationwide survey from the EGUIDE project

著者 (42件)： Ichihashi Kayo (Department of Neuropsychiatry, University of Tokyo Hospital, 7-3-1 Hongo, Tokyo 113-8655, Japan) ,  Kyou Yoshitaka (Department of Psychiatry, Kitasato University, School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0374, Japan) ,  Hasegawa Naomi (Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, Tokyo 187-8553, Japan) ,  Yasui-Furukori Norio (Department of Psychiatry, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Shimotsuga, Tochigi 321-0293, Japan) ,  Shimizu Yoshihito (Department of Pharmacy, Kanazawa Medical University Hospital, 1-1 Daigaku, Uchinada, Kahoku, Ishikawa 920-0293, Japan) ,  Hori Hikaru (Department of Psychiatry, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jyonan-ku, Fukuoka city, Fukuoka 814-0180, Japan) ,  Hashimoto Naoki (Department of Psychiatry, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo 060-8638, Japan) ,  Ide Kenta (Department of Hospital Pharmacy, Hospital of University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu-shi, Fukuoka 807-8555, Japan) ,  Imamura Yayoi (Department of Neuropsychiatry, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo 181-8611, Japan) ,  Yamada Hisashi (Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, Tokyo 187-8553, Japan) ,  Yamada Hisashi (Department of Neuropsychiatry, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan) ,  Ochi Shinichiro (Department of Neuropsychiatry, Molecules and Function, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime 791-0295, Japan) ,  Iga Jun-ichi (Department of Neuropsychiatry, Molecules and Function, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime 791-0295, Japan) ,  Takaesu Yoshikazu (Department of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0215, Japan) ,  Ohi Kazutaka (Department of Psychiatry, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, Gifu 501-1194, Japan) ,  Tsuboi Takashi (Department of Neuropsychiatry, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo 181-8611, Japan) ,  Iida Hitoshi (Department of Psychiatry, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jyonan-ku, Fukuoka city, Fukuoka 814-0180, Japan) ,  Yamagata Hirotaka (Division of Neuropsychiatry, Department of Neuroscience Yamaguchi University School of Medicine, 1-1-1 Minami-kogushi, Ube, Yamaguchi 755-8505, Japan) ,  Hishimoto Akitoyo (Department of Psychiatry, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, Yokohama 236-0004, Japan) ,  Horai Tadasu (Department of Psychiatry, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe-city, Hyogo, Japan) ,  Usami Masahide (Department of Child and Adolescent Psychiatry, Kohnodai Hospital, National Center for Global Health and Medicine, 1-7-1 Kohnodai, Ichikawa, Chiba 272-8516, Japan) ,  Makinodan Manabu (Department of Psychiatry, Nara Medical University School of Medicine, 840 Shijocho, Kashihara, Nara 634-8522, Japan) ,  Nagasawa Tatsuya (Department of NeuroPsychiatry Kanazawa Medical University, 1-1 Daigaku, Uchinada-machi, Ishikawa 920-0293, Japan) ,  Komatsu Hiroshi (Department of Psychiatry, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8573, Japan) ,  Kido Mikio (Toyama City Hospital, 2-1 Imaizumihokubuchou, Toyama, Toyama 939-8511, Japan) ,  Kido Mikio (Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, 2630, Sugitani, Toyama, Toyama 930-0194, Japan) ,  Muraoka Hiroyuki (Department of Psychiatry, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan) ,  Atake Kiyokazu (Nippon Telegraph and Telephone West Corporation Kyushu Health Administration Center, 13-8 DOIMACHI Bld. 2F, Kamikawabatamachi, Hakata-Ku, Fukuoka 812-0026, Japan) ,  Takeshima Masahiro (Department of Neuropsychiatry, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita city, Akita 010-8543, Japan) ,  Kubota Chika (National Center of Neurology and Psychiatry Hospital, 4-1-1 Ogawahigashi, Kodaira, Tokyo 187-8553, Japan) ,  Inagaki Takahiko (Adolescent Mental Health Service, Biwako Hospital, 1-8-5 Sakamoto, Otsu, Shiga 520-0113, Japan) ,  Inagaki Takahiko (Department of Psychiatry, Shiga University of Medical Science, Seta-Tsukinowa cho, Otsu, Shiga 520-2192, Japan) ,  Tamai Shinichiro (Department of NeuroPsychiatry, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashidai, Fuchu, Tokyo 183-8524, Japan) ,  Kishimoto Taishiro (Hills Joint Research Laboratory for Future Preventive Medicine and Wellness, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo 160-8582, Japan) ,  Furihata Ryuji (Kyoto University Health Service, Yoshida-honmachi, Sakyo-ku, Kyoto 606-8501, Japan) ,  Matsumoto Junya (Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, Tokyo 187-8553, Japan) ,  Miura Kenichiro (Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, Tokyo 187-8553, Japan) ,  Inada Ken (Department of Psychiatry, Kitasato University, School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0374, Japan) ,  Inada Ken (Department of Psychiatry, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan) ,  Watanabe Koichiro (Department of Neuropsychiatry, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo 181-8611, Japan) ,  Kasai Kiyoto (Department of Neuropsychiatry, University of Tokyo Hospital, 7-3-1 Hongo, Tokyo 113-8655, Japan) ,  Hashimoto Ryota (Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, Tokyo 187-8553, Japan)
資料名： Asian Journal of Psychiatry  (Asian Journal of Psychiatry)
巻： 69  ページ： Null  発行年： 2022年 
JST資料番号： W2878A  ISSN： 1876-2018  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： オランダ (NLD)  言語： 英語 (EN)

抄録/ポイント： いくつかのガイドラインは,毎日の薬物療法が統合失調症と主要な抑鬱障害の治療の重要な部分であるが,pro re nata(PRN)処方に関する報告はほとんどない。本研究の目的は,統合失調症と主要なうつ病性障害の治療に対する向精神性PRN処方を受けている患者の特徴を明らかにすることである。退院時の精神病的PRN処方の有無,各診断のためのPRN処方を受けている患者の年齢と性別,およびPRN処方と日常の日常向精神薬の間の関係を評価するために,精神科治療(EGUIDE)プロジェクトにおける普及と教育のためのガイドラインの有効性からデータを使用した。精神向性PRN処方率は,退院時に主要な抑鬱障害を有する1248人の患者の間で,統合失調症の2617人の患者と31.1%の間で29.9%であった。統合失調症において,向精神性PRN処方率は65歳以上の患者に対して21.6%であり,他の年齢群より低かった。主要な抑鬱性障害において,向精神性PRN処方率は女性患者に対して34.2%であり,男性患者(25.5%)より有意に高かった。統合失調症では,向精神性PRN処方と複数の向精神薬の定期的使用との間に関連があった。精神刺激性PRN処方は,統合失調症の高齢患者で一般的であり,主要な抑鬱障害の女性患者でより一般的であった。統合失調症において,向精神性PRN処方は向精神薬の多剤性をもたらした。証拠の蓄積と適切なPRN処方に関する教育の提供にはさらなる研究が必要である。Copyright 2022 Elsevier B.V., Amsterdam. All rights reserved. Translated from English into Japanese by JST.【JST・京大機械翻訳】

シソーラス用語： *向精神薬 ,  処方 ,  精神病 ,  *統合失調症 ,  男性 ,  薬物療法 ,  刺激性 ,  屈性 ,  *うつ病 ,  有効性 ,  指針
準シソーラス用語： 大うつ病性障害 ,  精神科 ,  高齢患者 ,  *うつ病性障害 , 【Automatic Indexing@JST】

著者キーワード (6件)： うつ病 ,  EGUIDEプロジェクト ,  多剤 ,  Pro re nata ,  向精神薬 ,  統合失調症

分類 (2件)： 医療制度  (GB04020H) ,  精神障害  (GR03000A)

タイトルに関連する用語 (9件)： 統合失調症 ,  大うつ病性障害 ,  治療 ,  退院 ,  向精神薬 ,  投与 ,  患者 ,  プロジェクト ,  調査